Home » Epigenomics Wins FDA Approval for Epi proColon
Epigenomics Wins FDA Approval for Epi proColon
The FDA has approved Epigenomics AG’s colorectal cancer screening blood test Epi proColon, the German-American diagnostics company announced Wednesday.
The test will be made available in the U.S. as part of a joint commercialization agreement with Polymedco.
The test is a noninvasive alternative for patients who would rather not undergo colonoscopies or fecal immunochemical tests. — Anisa Jibrell
Upcoming Events
-
07May
-
14May
-
30May